You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRivaroxaban
Accession NumberDB06228
TypeSmall Molecule
GroupsApproved
DescriptionRivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Structure
Thumb
Synonyms
BAY 59-7939
BAY59-7939
Xarelto
External Identifiers
  • BAY 59-7939
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
XareltoFilm-coated tablet15 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
Xareltotablet, film coated10 mg/1oralCardinal Health2011-07-01Not applicableUs
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet20 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet15 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
Xareltotablet, film coated15 mg/1oralJanssen Pharmaceuticals, Inc.2011-11-04Not applicableUs
XareltoFilm-coated tablet20 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
Xareltotablet10 mgoralBayer Inc2008-09-16Not applicableCanada
XareltoFilm-coated tablet15 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
Xareltotablet, film coated20 mg/1oralCardinal Health2011-11-05Not applicableUs
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet20 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
Xareltotablet, film coated20 mg/1oralJanssen Pharmaceuticals, Inc.2011-11-05Not applicableUs
XareltoFilm-coated tablet20 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet15 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
Xareltotablet15 mgoralBayer Inc2012-01-17Not applicableCanada
Xareltotablet, film coated15 mg/1oralCardinal Health2011-11-04Not applicableUs
XareltoFilm-coated tablet15 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet15 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
Xareltotablet, film coated10 mg/1oralJanssen Pharmaceuticals, Inc.2011-07-01Not applicableUs
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet15 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet20 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet15 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
Xareltotablet20 mgoralBayer Inc2012-01-17Not applicableCanada
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet15 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet20 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet20 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltokitJanssen Pharmaceuticals, Inc.2014-09-16Not applicableUs
XareltoFilm-coated tablet20 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet2.5 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
XareltoFilm-coated tablet10 mgOral useBayer Pharma Ag2008-09-30Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
XareltoBayer Inc
SaltsNot Available
Categories
UNII9NDF7JZ4M3
CAS number366789-02-8
WeightAverage: 435.881
Monoisotopic: 435.065569098
Chemical FormulaC19H18ClN3O5S
InChI KeyInChIKey=KGFYHTZWPPHNLQ-AWEZNQCLSA-N
InChI
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
IUPAC Name
5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide
SMILES
ClC1=CC=C(S1)C(=O)NC[[email protected]]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassOxazinanes
Sub ClassMorpholines
Direct ParentPhenylmorpholines
Alternative Parents
Substituents
  • Phenylmorpholine
  • Thiophene carboxylic acid or derivatives
  • Thiophene carboxamide
  • 2,5-disubstituted thiophene
  • Benzenoid
  • Oxazolidinone
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Thiophene
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationRivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (<30mL/min).
PharmacodynamicsRivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.
Mechanism of actionRivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.
Related Articles
AbsorptionFollowing oral administration, rivaroxaban is rapidly absorbed and reaches peak plasma concentration in 2-4 hours. Bioavailability of the 10 mg dose is >80%. However, the 15-20 mg dose have a lower bioavailability if taken in the fasted state and consequently should be taken with food.
Volume of distribution

The steady state Vd is 50 L

Protein bindingPlasma protein binding is about 92% to 95%
Metabolism

Approximately two-thirds of the dose is metabolized. It is metabolized by CYP3A4, CYP3A5, CYP2J2 and CYP-independant mechanisms

Route of eliminationApproximately two-thirds of rivaroxaban is excreted into urine (via active tubular secretion in which approximately 36% as unchanged drug and 30% as inactive metabolism). The remaining third of the administered dose is excreted via feces in which 7% is in the form of unchanged drug and 21% as inactive metabolites.
Half lifeThe terminal half life is 5-9 hours in adults and 11-13 hours in the elderly.
Clearance

Systemic clearance is approximately 10 L/h, so rivaroxaban is considered a drug with low clearance. Renal clearance is ~3-4 L/h.

ToxicityExcessive bleeding. Overdosages should be treated using activated charcoal and supportive measures such as mechanical compression and hemodynamic support. If bleeding is not controlled, the following procoagulants can be administered: activated prothrombin complex concentrate, prothrombin complex concentrate and recombinant factor VIIa. There is also a higher chance of post procedural hemorrhage compared to enoxaparin (1.55% vs. 1.39% respectively).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9462
Caco-2 permeable+0.6822
P-glycoprotein substrateNon-substrate0.5691
P-glycoprotein inhibitor IInhibitor0.6325
P-glycoprotein inhibitor IIInhibitor0.5601
Renal organic cation transporterNon-inhibitor0.7562
CYP450 2C9 substrateNon-substrate0.7866
CYP450 2D6 substrateNon-substrate0.8761
CYP450 3A4 substrateSubstrate0.5964
CYP450 1A2 substrateNon-inhibitor0.6469
CYP450 2C9 inhibitorNon-inhibitor0.7035
CYP450 2D6 inhibitorNon-inhibitor0.7516
CYP450 2C19 inhibitorInhibitor0.6475
CYP450 3A4 inhibitorNon-inhibitor0.6667
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7463
Ames testNon AMES toxic0.6162
CarcinogenicityNon-carcinogens0.8838
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.4353 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8938
hERG inhibition (predictor II)Inhibitor0.6205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Film-coated tabletOral use10 mg
Film-coated tabletOral use15 mg
Film-coated tabletOral use2.5 mg
Film-coated tabletOral use20 mg
Kit
Tabletoral
Tabletoral10 mg
Tabletoral15 mg
Tabletoral20 mg
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral20 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2396561 No2008-10-142020-12-11Canada
CA2547113 No2012-01-242024-11-13Canada
US7157456 No2001-02-082021-02-08Us
US7585860 No2000-12-112020-12-11Us
US7592339 No2000-12-112020-12-11Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP1.74ALOGPS
logP1.9ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area88.18 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.74 m3·mol-1ChemAxon
Polarizability43.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Prabhudas BODHURI, Gamini Weeratunga, “PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF.” U.S. Patent US20100273790, issued October 28, 2010.

US20100273790
General References
  1. Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM: Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . [PubMed:18491993 ]
  2. Alban S: Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des. 2008;14(12):1152-75. [PubMed:18473863 ]
  3. Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E: Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. [PubMed:19846028 ]
  4. Imberti D, Dall'Asta C, Pierfranceschi MG: Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009 Dec;4(6):471-7. doi: 10.1007/s11739-009-0293-9. [PubMed:19696978 ]
  5. Alexander D, Jeremias A: Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opin Investig Drugs. 2011 Jun;20(6):849-57. doi: 10.1517/13543784.2011.580274. Epub 2011 May 10. [PubMed:21554163 ]
  6. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472 ]
External Links
ATC CodesB01AF01
AHFS Codes
  • 20.12.04.14
PDB EntriesNot Available
FDA labelDownload (537 KB)
MSDSDownload (480 KB)
Interactions
Drug Interactions
Drug
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Rivaroxaban.
AbciximabAbciximab may increase the anticoagulant activities of Rivaroxaban.
AceclofenacAceclofenac may increase the anticoagulant activities of Rivaroxaban.
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Rivaroxaban.
AcetaminophenThe serum concentration of Rivaroxaban can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Rivaroxaban.
AdapaleneAdapalene may increase the anticoagulant activities of Rivaroxaban.
AfatinibThe serum concentration of Rivaroxaban can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Rivaroxaban can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Rivaroxaban can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Rivaroxaban can be increased when it is combined with Alfentanil.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Rivaroxaban.
AllylestrenolThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Allylestrenol.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Rivaroxaban.
AlprostadilAlprostadil may increase the anticoagulant activities of Rivaroxaban.
AlteplaseAlteplase may increase the anticoagulant activities of Rivaroxaban.
AltrenogestThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Altrenogest.
ALX-0081ALX-0081 may increase the anticoagulant activities of Rivaroxaban.
AmantadineThe serum concentration of Rivaroxaban can be increased when it is combined with Amantadine.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Rivaroxaban.
Aminohippuric acidThe serum concentration of Rivaroxaban can be increased when it is combined with Aminohippuric acid.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Rivaroxaban.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Rivaroxaban.
AmiodaroneThe serum concentration of Rivaroxaban can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Rivaroxaban.
AmlodipineThe serum concentration of Rivaroxaban can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Rivaroxaban can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Rivaroxaban can be increased when it is combined with Amsacrine.
AnagrelideAnagrelide may increase the anticoagulant activities of Rivaroxaban.
AncrodAncrod may increase the anticoagulant activities of Rivaroxaban.
AnistreplaseAnistreplase may increase the anticoagulant activities of Rivaroxaban.
AntipyrineAntipyrine may increase the anticoagulant activities of Rivaroxaban.
Antithrombin III humanAntithrombin III human may increase the anticoagulant activities of Rivaroxaban.
ApixabanApixaban may increase the anticoagulant activities of Rivaroxaban.
ApremilastApremilast may increase the anticoagulant activities of Rivaroxaban.
AprepitantThe serum concentration of Rivaroxaban can be increased when it is combined with Aprepitant.
AprotininThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Aprotinin.
ArdeparinArdeparin may increase the anticoagulant activities of Rivaroxaban.
ArgatrobanArgatroban may increase the anticoagulant activities of Rivaroxaban.
AstaxanthinAstaxanthin may increase the anticoagulant activities of Rivaroxaban.
AstemizoleThe serum concentration of Rivaroxaban can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Rivaroxaban can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Rivaroxaban can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Rivaroxaban can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Rivaroxaban.
AzapropazoneAzapropazone may increase the anticoagulant activities of Rivaroxaban.
AzelastineAzelastine may increase the anticoagulant activities of Rivaroxaban.
AzithromycinThe serum concentration of Rivaroxaban can be increased when it is combined with Azithromycin.
BalsalazideBalsalazide may increase the anticoagulant activities of Rivaroxaban.
BatroxobinBatroxobin may increase the anticoagulant activities of Rivaroxaban.
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Rivaroxaban.
BecaplerminBecaplermin may increase the anticoagulant activities of Rivaroxaban.
BemiparinBemiparin may increase the anticoagulant activities of Rivaroxaban.
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Rivaroxaban.
BenzocaineThe serum concentration of Rivaroxaban can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Rivaroxaban can be increased when it is combined with Bepridil.
BeraprostBeraprost may increase the anticoagulant activities of Rivaroxaban.
BexaroteneThe serum concentration of Rivaroxaban can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Rivaroxaban can be increased when it is combined with Biperiden.
BivalirudinBivalirudin may increase the anticoagulant activities of Rivaroxaban.
BoceprevirThe serum concentration of Rivaroxaban can be decreased when it is combined with Boceprevir.
BortezomibThe metabolism of Rivaroxaban can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Rivaroxaban can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Rivaroxaban can be increased when it is combined with Bosutinib.
BromfenacBromfenac may increase the anticoagulant activities of Rivaroxaban.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Rivaroxaban.
BuprenorphineThe serum concentration of Rivaroxaban can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Rivaroxaban can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Rivaroxaban can be increased when it is combined with Cabazitaxel.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Rivaroxaban.
CaffeineThe serum concentration of Rivaroxaban can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Rivaroxaban can be increased when it is combined with Candesartan.
CangrelorCangrelor may increase the anticoagulant activities of Rivaroxaban.
CaptoprilThe serum concentration of Rivaroxaban can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Rivaroxaban can be decreased when it is combined with Carbamazepine.
CarprofenCarprofen may increase the anticoagulant activities of Rivaroxaban.
CarvedilolThe serum concentration of Rivaroxaban can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Rivaroxaban can be increased when it is combined with Caspofungin.
CastanospermineCastanospermine may increase the anticoagulant activities of Rivaroxaban.
CelecoxibCelecoxib may increase the anticoagulant activities of Rivaroxaban.
CeritinibThe serum concentration of Rivaroxaban can be increased when it is combined with Ceritinib.
CertoparinCertoparin may increase the anticoagulant activities of Rivaroxaban.
ChloroquineChloroquine may increase the anticoagulant activities of Rivaroxaban.
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Rivaroxaban.
ChlorpromazineThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Rivaroxaban can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Rivaroxaban can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Rivaroxaban can be increased when it is combined with Cilazapril.
CilostazolCilostazol may increase the anticoagulant activities of Rivaroxaban.
CimetidineThe serum concentration of Rivaroxaban can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Rivaroxaban can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Rivaroxaban.
CitalopramThe serum concentration of Rivaroxaban can be increased when it is combined with Citalopram.
Citric AcidCitric Acid may increase the anticoagulant activities of Rivaroxaban.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Rivaroxaban.
ClarithromycinThe serum concentration of Rivaroxaban can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Rivaroxaban can be decreased when combined with Clemastine.
ClofazimineThe serum concentration of Rivaroxaban can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Rivaroxaban.
ClonixinClonixin may increase the anticoagulant activities of Rivaroxaban.
ClopidogrelClopidogrel may increase the anticoagulant activities of Rivaroxaban.
ClotrimazoleThe metabolism of Rivaroxaban can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Rivaroxaban can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Rivaroxaban can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Rivaroxaban can be increased when it is combined with Colforsin.
CollagenaseThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Collagenase.
ConivaptanThe serum concentration of Rivaroxaban can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Rivaroxaban.
CrizotinibThe metabolism of Rivaroxaban can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Rivaroxaban.
CyclophosphamideThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Cyclophosphamide.
CyclophosphamideThe serum concentration of Rivaroxaban can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Rivaroxaban.
CyclosporineThe metabolism of Rivaroxaban can be decreased when combined with Cyclosporine.
D-LimoneneD-Limonene may increase the anticoagulant activities of Rivaroxaban.
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Rivaroxaban.
DabrafenibThe serum concentration of Rivaroxaban can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Rivaroxaban can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Rivaroxaban can be increased when it is combined with Dactinomycin.
DalteparinDalteparin may increase the anticoagulant activities of Rivaroxaban.
DanaparoidDanaparoid may increase the anticoagulant activities of Rivaroxaban.
DarunavirThe metabolism of Rivaroxaban can be decreased when combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Rivaroxaban.
DaunorubicinThe serum concentration of Rivaroxaban can be decreased when it is combined with Daunorubicin.
DeferasiroxThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Deferasirox.
DeferasiroxThe serum concentration of Rivaroxaban can be decreased when it is combined with Deferasirox.
DefibrotideDefibrotide may increase the anticoagulant activities of Rivaroxaban.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Rivaroxaban.
DelavirdineThe metabolism of Rivaroxaban can be decreased when combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Deoxycholic Acid.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Rivaroxaban.
DesirudinDesirudin may increase the anticoagulant activities of Rivaroxaban.
DesloratadineThe serum concentration of Rivaroxaban can be increased when it is combined with Desloratadine.
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Rivaroxaban.
DesogestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Desogestrel.
DexamethasoneThe serum concentration of Rivaroxaban can be decreased when it is combined with Dexamethasone.
DextranDextran may increase the anticoagulant activities of Rivaroxaban.
Dextran 40Dextran 40 may increase the anticoagulant activities of Rivaroxaban.
Dextran 70Dextran 70 may increase the anticoagulant activities of Rivaroxaban.
Dextran 75Dextran 75 may increase the anticoagulant activities of Rivaroxaban.
DextromethorphanThe serum concentration of Rivaroxaban can be increased when it is combined with Dextromethorphan.
DiclofenacDiclofenac may increase the anticoagulant activities of Rivaroxaban.
DicoumarolDicoumarol may increase the anticoagulant activities of Rivaroxaban.
DienestrolDienestrol may decrease the anticoagulant activities of Rivaroxaban.
DienogestThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Dienogest.
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Rivaroxaban.
DiflunisalDiflunisal may increase the anticoagulant activities of Rivaroxaban.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Rivaroxaban.
DigoxinThe serum concentration of Rivaroxaban can be decreased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Rivaroxaban.
DihydroergotamineThe metabolism of Rivaroxaban can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Rivaroxaban can be decreased when combined with Diltiazem.
DipyridamoleDipyridamole may increase the anticoagulant activities of Rivaroxaban.
DitazoleDitazole may increase the anticoagulant activities of Rivaroxaban.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Rivaroxaban.
DoxazosinThe serum concentration of Rivaroxaban can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Rivaroxaban.
DoxorubicinThe serum concentration of Rivaroxaban can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Rivaroxaban can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Rivaroxaban can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Rivaroxaban can be decreased when combined with Dronedarone.
DrospirenoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Drospirenone.
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Rivaroxaban.
DroxicamDroxicam may increase the anticoagulant activities of Rivaroxaban.
DydrogesteroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Dydrogesterone.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Rivaroxaban.
Edetic AcidEdetic Acid may increase the anticoagulant activities of Rivaroxaban.
EdoxabanEdoxaban may increase the anticoagulant activities of Rivaroxaban.
EfavirenzThe serum concentration of Rivaroxaban can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Rivaroxaban can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Rivaroxaban can be increased when it is combined with Enalapril.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Rivaroxaban.
EnoxaparinEnoxaparin may increase the anticoagulant activities of Rivaroxaban.
EnzalutamideThe serum concentration of Rivaroxaban can be decreased when it is combined with Enzalutamide.
EpinastineEpinastine may increase the anticoagulant activities of Rivaroxaban.
EpirizoleEpirizole may increase the anticoagulant activities of Rivaroxaban.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Rivaroxaban.
EpoprostenolThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Rivaroxaban.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Rivaroxaban.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Rivaroxaban.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Rivaroxaban.
ErythromycinThe metabolism of Rivaroxaban can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Rivaroxaban can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Rivaroxaban.
EstradiolEstradiol may decrease the anticoagulant activities of Rivaroxaban.
EstramustineThe serum concentration of Rivaroxaban can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Rivaroxaban can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Rivaroxaban can be decreased when it is combined with Estrone.
EtanerceptEtanercept may increase the anticoagulant activities of Rivaroxaban.
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Rivaroxaban.
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Rivaroxaban.
EtodolacEtodolac may increase the anticoagulant activities of Rivaroxaban.
EtofenamateEtofenamate may increase the anticoagulant activities of Rivaroxaban.
EtonogestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Etonogestrel.
EtoposideThe serum concentration of Rivaroxaban can be increased when it is combined with Etoposide.
EtoricoxibEtoricoxib may increase the anticoagulant activities of Rivaroxaban.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Rivaroxaban.
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Rivaroxaban.
exisulindexisulind may increase the anticoagulant activities of Rivaroxaban.
FelodipineThe serum concentration of Rivaroxaban can be increased when it is combined with Felodipine.
FenbufenFenbufen may increase the anticoagulant activities of Rivaroxaban.
FenoprofenFenoprofen may increase the anticoagulant activities of Rivaroxaban.
FentanylThe serum concentration of Rivaroxaban can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Rivaroxaban can be increased when it is combined with Fexofenadine.
FibrinolysinFibrinolysin may increase the anticoagulant activities of Rivaroxaban.
FidaxomicinThe serum concentration of Rivaroxaban can be increased when it is combined with Fidaxomicin.
FloctafenineFloctafenine may increase the anticoagulant activities of Rivaroxaban.
FluconazoleThe metabolism of Rivaroxaban can be decreased when combined with Fluconazole.
FlunixinFlunixin may increase the anticoagulant activities of Rivaroxaban.
FluoxetineThe serum concentration of Rivaroxaban can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Rivaroxaban can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Rivaroxaban can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Rivaroxaban can be increased when it is combined with Flurazepam.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Rivaroxaban.
FluvoxamineThe metabolism of Rivaroxaban can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Rivaroxaban.
FosamprenavirThe metabolism of Rivaroxaban can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Rivaroxaban can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Rivaroxaban can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Rivaroxaban can be increased when it is combined with Fusidic Acid.
GarlicThe serum concentration of Rivaroxaban can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Rivaroxaban can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Rivaroxaban can be increased when it is combined with Genistein.
GestodeneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Gestodene.
GlyburideThe serum concentration of Rivaroxaban can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Rivaroxaban can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Rivaroxaban can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Rivaroxaban can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Rivaroxaban can be increased when it is combined with Haloperidol.
HeminHemin may increase the anticoagulant activities of Rivaroxaban.
HeparinHeparin may increase the anticoagulant activities of Rivaroxaban.
HexestrolHexestrol may decrease the anticoagulant activities of Rivaroxaban.
HirulogHirulog may increase the anticoagulant activities of Rivaroxaban.
HMPL-004HMPL-004 may increase the anticoagulant activities of Rivaroxaban.
HydrocortisoneThe serum concentration of Rivaroxaban can be increased when it is combined with Hydrocortisone.
Hydroxyprogesterone caproateThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Hydroxyprogesterone caproate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rivaroxaban.
IbudilastIbudilast may increase the anticoagulant activities of Rivaroxaban.
IbuprofenIbuprofen may increase the anticoagulant activities of Rivaroxaban.
IbuproxamIbuproxam may increase the anticoagulant activities of Rivaroxaban.
IcatibantIcatibant may increase the anticoagulant activities of Rivaroxaban.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Rivaroxaban.
IdelalisibThe serum concentration of Rivaroxaban can be increased when it is combined with Idelalisib.
IfenprodilIfenprodil may increase the anticoagulant activities of Rivaroxaban.
IloprostIloprost may increase the anticoagulant activities of Rivaroxaban.
IloprostThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Iloprost.
ImatinibThe metabolism of Rivaroxaban can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Rivaroxaban.
IndinavirThe serum concentration of Rivaroxaban can be decreased when it is combined with Indinavir.
IndomethacinIndomethacin may increase the anticoagulant activities of Rivaroxaban.
IndoprofenIndoprofen may increase the anticoagulant activities of Rivaroxaban.
IsavuconazoniumThe metabolism of Rivaroxaban can be decreased when combined with Isavuconazonium.
IsoxicamIsoxicam may increase the anticoagulant activities of Rivaroxaban.
IsradipineThe metabolism of Rivaroxaban can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Rivaroxaban can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Rivaroxaban can be increased when it is combined with Ivermectin.
KebuzoneKebuzone may increase the anticoagulant activities of Rivaroxaban.
KetamineThe serum concentration of Rivaroxaban can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may increase the anticoagulant activities of Rivaroxaban.
KetorolacKetorolac may increase the anticoagulant activities of Rivaroxaban.
LansoprazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Rivaroxaban can be increased when it is combined with Lapatinib.
LeflunomideLeflunomide may increase the anticoagulant activities of Rivaroxaban.
LepirudinLepirudin may increase the anticoagulant activities of Rivaroxaban.
LevofloxacinThe serum concentration of Rivaroxaban can be increased when it is combined with Levofloxacin.
LevonorgestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Levonorgestrel.
LevothyroxineThe serum concentration of Rivaroxaban can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Rivaroxaban can be increased when it is combined with Lidocaine.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Rivaroxaban.
LiothyronineThe serum concentration of Rivaroxaban can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Rivaroxaban can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Rivaroxaban can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Rivaroxaban can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Rivaroxaban can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Rivaroxaban can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Rivaroxaban can be increased when it is combined with Loratadine.
LornoxicamLornoxicam may increase the anticoagulant activities of Rivaroxaban.
LosartanThe serum concentration of Rivaroxaban can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Rivaroxaban.
LovastatinThe metabolism of Rivaroxaban can be decreased when combined with Lovastatin.
LoxoprofenLoxoprofen may increase the anticoagulant activities of Rivaroxaban.
LuliconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Rivaroxaban can be decreased when it is combined with Lumacaftor.
LumiracoxibLumiracoxib may increase the anticoagulant activities of Rivaroxaban.
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Rivaroxaban.
MaprotilineThe serum concentration of Rivaroxaban can be increased when it is combined with Maprotiline.
MasoprocolMasoprocol may increase the anticoagulant activities of Rivaroxaban.
MebendazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Mebendazole.
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Rivaroxaban.
MedrogestoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medrogestone.
Medroxyprogesterone acetateThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Rivaroxaban.
MefloquineThe serum concentration of Rivaroxaban can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Rivaroxaban can be increased when it is combined with Megestrol acetate.
MeloxicamMeloxicam may increase the anticoagulant activities of Rivaroxaban.
MeprobamateThe serum concentration of Rivaroxaban can be increased when it is combined with Meprobamate.
MesalazineMesalazine may increase the anticoagulant activities of Rivaroxaban.
MestranolMestranol may decrease the anticoagulant activities of Rivaroxaban.
MetamizoleMetamizole may increase the anticoagulant activities of Rivaroxaban.
MethadoneThe serum concentration of Rivaroxaban can be increased when it is combined with Methadone.
MetoprololThe serum concentration of Rivaroxaban can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Rivaroxaban can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Rivaroxaban.
MidazolamThe serum concentration of Rivaroxaban can be decreased when it is combined with Midazolam.
MifepristoneThe metabolism of Rivaroxaban can be decreased when combined with Mifepristone.
MilrinoneMilrinone may increase the anticoagulant activities of Rivaroxaban.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Rivaroxaban.
MitomycinThe serum concentration of Rivaroxaban can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Rivaroxaban can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Rivaroxaban can be decreased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Rivaroxaban can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Rivaroxaban can be increased when it is combined with Morphine.
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Rivaroxaban.
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Rivaroxaban.
NabumetoneNabumetone may increase the anticoagulant activities of Rivaroxaban.
NadroparinNadroparin may increase the anticoagulant activities of Rivaroxaban.
NafcillinThe serum concentration of Rivaroxaban can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may increase the anticoagulant activities of Rivaroxaban.
NaltrexoneThe serum concentration of Rivaroxaban can be increased when it is combined with Naltrexone.
NaproxenNaproxen may increase the anticoagulant activities of Rivaroxaban.
NaringeninThe serum concentration of Rivaroxaban can be increased when it is combined with Naringenin.
NCX 4016NCX 4016 may increase the anticoagulant activities of Rivaroxaban.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Rivaroxaban.
NefazodoneThe serum concentration of Rivaroxaban can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Rivaroxaban can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Rivaroxaban can be increased when it is combined with Neostigmine.
NepafenacNepafenac may increase the anticoagulant activities of Rivaroxaban.
NetupitantThe serum concentration of Rivaroxaban can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Rivaroxaban can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Rivaroxaban can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Rivaroxaban can be decreased when it is combined with Nifedipine.
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Rivaroxaban.
NilotinibThe metabolism of Rivaroxaban can be decreased when combined with Nilotinib.
NimesulideNimesulide may increase the anticoagulant activities of Rivaroxaban.
NintedanibThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Nintedanib.
NisoldipineThe serum concentration of Rivaroxaban can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Rivaroxaban can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Rivaroxaban can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Rivaroxaban can be decreased when it is combined with Norethisterone.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Rivaroxaban.
ObinutuzumabThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Obinutuzumab.
OlaparibThe metabolism of Rivaroxaban can be decreased when combined with Olaparib.
OlopatadineOlopatadine may increase the anticoagulant activities of Rivaroxaban.
OlsalazineOlsalazine may increase the anticoagulant activities of Rivaroxaban.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Omacetaxine mepesuccinate.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Rivaroxaban.
OmeprazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Omeprazole.
OrgoteinOrgotein may increase the anticoagulant activities of Rivaroxaban.
OsimertinibThe serum concentration of Rivaroxaban can be increased when it is combined with Osimertinib.
OtamixabanOtamixaban may increase the anticoagulant activities of Rivaroxaban.
OxaprozinOxaprozin may increase the anticoagulant activities of Rivaroxaban.
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Rivaroxaban.
P-NitrophenolThe serum concentration of Rivaroxaban can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Rivaroxaban can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Rivaroxaban can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Rivaroxaban can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Pantoprazole.
ParecoxibParecoxib may increase the anticoagulant activities of Rivaroxaban.
ParnaparinParnaparin may increase the anticoagulant activities of Rivaroxaban.
ParoxetineThe serum concentration of Rivaroxaban can be increased when it is combined with Paroxetine.
PentobarbitalThe serum concentration of Rivaroxaban can be decreased when it is combined with Pentobarbital.
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Rivaroxaban.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Rivaroxaban.
PerindoprilThe serum concentration of Rivaroxaban can be increased when it is combined with Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Pethidine.
PhenindionePhenindione may increase the anticoagulant activities of Rivaroxaban.
PhenobarbitalThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenobarbital.
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Rivaroxaban.
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Rivaroxaban.
PhenytoinThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenytoin.
PimecrolimusPimecrolimus may increase the anticoagulant activities of Rivaroxaban.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Rivaroxaban.
PirfenidonePirfenidone may increase the anticoagulant activities of Rivaroxaban.
PiroxicamPiroxicam may increase the anticoagulant activities of Rivaroxaban.
PlasminPlasmin may increase the anticoagulant activities of Rivaroxaban.
Platelet Activating FactorThe serum concentration of Rivaroxaban can be decreased when it is combined with Platelet Activating Factor.
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Rivaroxaban.
PonatinibThe serum concentration of Rivaroxaban can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Posaconazole.
PrasugrelPrasugrel may increase the anticoagulant activities of Rivaroxaban.
PravastatinThe serum concentration of Rivaroxaban can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Rivaroxaban can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Rivaroxaban can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of Rivaroxaban can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Rivaroxaban can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Rivaroxaban can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Rivaroxaban can be increased when it is combined with Promethazine.
PropacetamolPropacetamol may increase the anticoagulant activities of Rivaroxaban.
PropafenoneThe serum concentration of Rivaroxaban can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Rivaroxaban can be increased when it is combined with Propranolol.
Protein CProtein C may increase the anticoagulant activities of Rivaroxaban.
ProtocatechualdehydeProtocatechualdehyde may increase the anticoagulant activities of Rivaroxaban.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Rivaroxaban.
PTC299PTC299 may increase the anticoagulant activities of Rivaroxaban.
QuercetinThe serum concentration of Rivaroxaban can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Rivaroxaban can be increased when it is combined with Quinacrine.
QuinestrolQuinestrol may decrease the anticoagulant activities of Rivaroxaban.
QuinidineThe serum concentration of Rivaroxaban can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Rivaroxaban can be increased when it is combined with Quinine.
RanitidineThe serum concentration of Rivaroxaban can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Rivaroxaban can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Rivaroxaban can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Rivaroxaban can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Rivaroxaban can be decreased when it is combined with Reserpine.
ResveratrolResveratrol may increase the anticoagulant activities of Rivaroxaban.
ReteplaseReteplase may increase the anticoagulant activities of Rivaroxaban.
ReviparinReviparin may increase the anticoagulant activities of Rivaroxaban.
RidogrelRidogrel may increase the anticoagulant activities of Rivaroxaban.
RifabutinThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Rivaroxaban can be increased when it is combined with Rilpivirine.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Rivaroxaban.
RitonavirThe serum concentration of Rivaroxaban can be decreased when it is combined with Ritonavir.
RofecoxibRofecoxib may increase the anticoagulant activities of Rivaroxaban.
RolapitantThe serum concentration of Rivaroxaban can be increased when it is combined with Rolapitant.
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Rivaroxaban.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Rivaroxaban.
SalicylamideSalicylamide may increase the anticoagulant activities of Rivaroxaban.
Salicylic acidSalicylic acid may increase the anticoagulant activities of Rivaroxaban.
SalsalateSalsalate may increase the anticoagulant activities of Rivaroxaban.
SaquinavirThe serum concentration of Rivaroxaban can be decreased when it is combined with Saquinavir.
SCH-530348SCH-530348 may increase the anticoagulant activities of Rivaroxaban.
ScopolamineThe serum concentration of Rivaroxaban can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Rivaroxaban can be increased when it is combined with Selegiline.
SelexipagSelexipag may increase the anticoagulant activities of Rivaroxaban.
SeratrodastSeratrodast may increase the anticoagulant activities of Rivaroxaban.
SertralineThe serum concentration of Rivaroxaban can be increased when it is combined with Sertraline.
SevofluraneSevoflurane may increase the anticoagulant activities of Rivaroxaban.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Rivaroxaban.
SildenafilThe metabolism of Rivaroxaban can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Rivaroxaban can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Rivaroxaban can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Rivaroxaban.
SirolimusThe serum concentration of Rivaroxaban can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Rivaroxaban can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Rivaroxaban can be increased when it is combined with Spironolactone.
SRT501SRT501 may increase the anticoagulant activities of Rivaroxaban.
St. John's WortThe metabolism of Rivaroxaban can be increased when combined with St. John&#39;s Wort.
StaurosporineThe serum concentration of Rivaroxaban can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Rivaroxaban can be increased when it is combined with Stiripentol.
StreptokinaseStreptokinase may increase the anticoagulant activities of Rivaroxaban.
StreptozocinThe serum concentration of Rivaroxaban can be decreased when it is combined with Streptozocin.
SugammadexSugammadex may increase the anticoagulant activities of Rivaroxaban.
SulfasalazineSulfasalazine may increase the anticoagulant activities of Rivaroxaban.
SulfinpyrazoneThe serum concentration of Rivaroxaban can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Rivaroxaban can be decreased when combined with Sulfisoxazole.
SulindacSulindac may increase the anticoagulant activities of Rivaroxaban.
SulodexideSulodexide may increase the anticoagulant activities of Rivaroxaban.
SumatriptanThe serum concentration of Rivaroxaban can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Rivaroxaban can be increased when it is combined with Sunitinib.
SuprofenSuprofen may increase the anticoagulant activities of Rivaroxaban.
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Rivaroxaban.
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Rivaroxaban.
TacrineThe serum concentration of Rivaroxaban can be increased when it is combined with Tacrine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Rivaroxaban.
TacrolimusThe serum concentration of Rivaroxaban can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Rivaroxaban can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Rivaroxaban can be increased when it is combined with Taurocholic Acid.
TelaprevirThe metabolism of Rivaroxaban can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Rivaroxaban can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Rivaroxaban can be increased when it is combined with Telmisartan.
TemsirolimusThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Temsirolimus.
TemsirolimusThe serum concentration of Rivaroxaban can be increased when it is combined with Temsirolimus.
TenecteplaseTenecteplase may increase the anticoagulant activities of Rivaroxaban.
TenoxicamTenoxicam may increase the anticoagulant activities of Rivaroxaban.
TepoxalinTepoxalin may increase the anticoagulant activities of Rivaroxaban.
TerazosinThe serum concentration of Rivaroxaban can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Rivaroxaban can be increased when it is combined with Terfenadine.
TeriflunomideTeriflunomide may increase the anticoagulant activities of Rivaroxaban.
TesmilifeneTesmilifene may increase the anticoagulant activities of Rivaroxaban.
TestosteroneThe serum concentration of Rivaroxaban can be increased when it is combined with Testosterone.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Rivaroxaban.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Rivaroxaban.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Rivaroxaban.
TiboloneTibolone may increase the anticoagulant activities of Rivaroxaban.
TicagrelorTicagrelor may increase the anticoagulant activities of Rivaroxaban.
TiclopidineTiclopidine may increase the anticoagulant activities of Rivaroxaban.
TinzaparinTinzaparin may increase the anticoagulant activities of Rivaroxaban.
TipranavirThe serum concentration of Rivaroxaban can be decreased when it is combined with Tipranavir.
TirofibanTirofiban may increase the anticoagulant activities of Rivaroxaban.
TocilizumabThe serum concentration of Rivaroxaban can be decreased when it is combined with Tocilizumab.
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Rivaroxaban.
TolmetinTolmetin may increase the anticoagulant activities of Rivaroxaban.
TolvaptanThe serum concentration of Rivaroxaban can be increased when it is combined with Tolvaptan.
TositumomabThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Tositumomab.
TranilastTranilast may increase the anticoagulant activities of Rivaroxaban.
TrapidilTrapidil may increase the anticoagulant activities of Rivaroxaban.
TrazodoneThe serum concentration of Rivaroxaban can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the anticoagulant activities of Rivaroxaban.
TreprostinilThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Treprostinil.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Rivaroxaban.
TrifluoperazineThe serum concentration of Rivaroxaban can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Rivaroxaban can be increased when it is combined with Triflupromazine.
TriflusalTriflusal may increase the anticoagulant activities of Rivaroxaban.
TrimethoprimThe serum concentration of Rivaroxaban can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Rivaroxaban.
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Rivaroxaban.
TroleandomycinThe serum concentration of Rivaroxaban can be increased when it is combined with Troleandomycin.
UrokinaseUrokinase may increase the anticoagulant activities of Rivaroxaban.
ValdecoxibValdecoxib may increase the anticoagulant activities of Rivaroxaban.
VenlafaxineThe metabolism of Rivaroxaban can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Rivaroxaban can be decreased when combined with Verapamil.
VinblastineThe serum concentration of Rivaroxaban can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Rivaroxaban can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Rivaroxaban can be increased when it is combined with Vinorelbine.
Vitamin EVitamin E may increase the anticoagulant activities of Rivaroxaban.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Rivaroxaban.
VoriconazoleThe metabolism of Rivaroxaban can be decreased when combined with Voriconazole.
WarfarinWarfarin may increase the anticoagulant activities of Rivaroxaban.
XimelagatranXimelagatran may increase the anticoagulant activities of Rivaroxaban.
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Rivaroxaban.
ZeranolZeranol may decrease the anticoagulant activities of Rivaroxaban.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Rivaroxaban.
ZileutonZileuton may increase the anticoagulant activities of Rivaroxaban.
ZimelidineThe serum concentration of Rivaroxaban can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Rivaroxaban can be decreased when combined with Ziprasidone.
ZomepiracZomepirac may increase the anticoagulant activities of Rivaroxaban.
Food Interactions
  • Food should be taken with the 15 mg and 20 mg tablet. Food increases the bioavailability of the 20 mg dose.
  • Foods with antiplatelet/anticoagulants properties such as horseradish, gingko, ginger, garlic, feverfew
  • St. John's Wort is a CYP3A4 inducer and will decrease levels of rivaroxaban

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serine-type endopeptidase activity
Specific Function:
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name:
F10
Uniprot ID:
P00742
Molecular Weight:
54731.255 Da
References
  1. Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI: Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010 Jun;44(6):1061-71. doi: 10.1345/aph.1M681. Epub 2010 Apr 27. [PubMed:20424181 ]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Mismetti P, Laporte S: [Rivaroxaban: clinical pharmacology]. Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S16-21. doi: 10.1016/S0750-7658(08)75142-6. [PubMed:19185782 ]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible for the epoxidation of endogenous cardiac arachidonic acid pools.
Gene Name:
CYP2J2
Uniprot ID:
P51589
Molecular Weight:
57610.165 Da
References
  1. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Walenga JM, Adiguzel C: Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010 Jun;64(7):956-67. doi: 10.1111/j.1742-1241.2009.02286.x. [PubMed:20584229 ]
  2. Chen T, Lam S: Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism. Cardiol Rev. 2009 Jul-Aug;17(4):192-7. doi: 10.1097/CRD.0b013e3181aa2154. [PubMed:19525681 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:18 / Updated on September 24, 2016 02:16